Please assess the completion status of the following clinical trial:

Trial Title: A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Myelodysplastic syndrome (de novo or secondary) fitting any of the recognized French-American-British classifications: refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia with white blood cells less than 13,000 /mm3~* International Prognostic Scoring System (IPSS) greater than or equal to 0.5 (Intermediate-1, Intermediate-2 or high risk) by bone marrow assessment and bone marrow cytogenetics within 28 days before study registration~* 20 years or older~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* Normal renal and hepatic function~Exclusion Criteria:~* Acute Myeloid Leukemia (AML) with bone marrow blasts greater than or equal to 30%~* Participants with a history of high-dose cytarabine (Ara-C) therapy (greater than 1,000 mg/m2/day)~* Participants administered adrenal cortex hormones or anabolic hormones within 7 days of study initiation~* Participants who have received a colony stimulating factor (CSF) formulation within 7 days of study initiation~* Active double cancer~* Uncontrolled cardiac disease or cognitive heart failure~* Uncontrolled restrictive or obstructive pulmonary disease~* Uncontrolled diabetes mellitus~* Active viral or bacterial infection~* Known positive serology for Human immunodeficiency virus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I: JNJ-30979754 15 mg/m2 (Type: EXPERIMENTAL): JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
- Phase I: JNJ-30979754 20 mg/m2 (Type: EXPERIMENTAL): JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
- Phase II: JNJ-30979754 20 mg/m2 (Type: EXPERIMENTAL): JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).